The Acute Effects of Low-dose TNF-α on Glucose Metabolism and β-cell Function in Humans

Rigshospitalet

Status: Completed

Conditions: Diabetes Type 2

Treatments: Other: Low-dose TNF-alpha

Study type: Interventional

Funder types: Other

Identifiers

NCT01953393

RH TAL

Details and patient eligibility

About

Type 2 diabetes is characterized by increased insulin resistance and impaired insulin secretion. In addition, type 2 diabetes is associated with low grade inflammation indicated by increased levels of proinflammatory cytokines such as TNF-α. TNF-α has previously been shown to impair peripheral insulin signaling in vitro and in vivo. However, it is unclear whether TNF-α may also affect endogenous glucose production (EGP) during fasting and glucose stimulated insulin secretion (GSIS) in vivo.

We hypothesized that low dose TNF-α would increase EGP and attenuate GSIS. Recombinant human TNF-α or placebo was infused in healthy, non-obese and non-diabetic young men (n=10) during a 4-hour basal period followed by an intravenous glucose tolerance test (IVGTT).

Sex: Male

Ages: 20 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy men
• Age 20-35

Exclusion criteria

• obesity (BMI>25)
• diabetes
• chronic disease